Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins

July 23, 2026 07:11 AM EDT R&DGLP-1 drugs Lil­ly's triple ag­o­nist heads to reg­u­la­tors af­ter two more Phase 3 obe­si­ty wins Elizabeth Cairns Senior biopharma journalist Re­ta­tru­tide, the obe­si­ty can­di­date that has shown the most pow­er­ful weight loss in late-stage tri­als, will be filed for ap­proval ear­ly next year, its de­vel­op­er … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER